ExpreS2ion to present in investor and R&D events in March
Hørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
5 March 2024 | Aktiespararna Stora Aktiedagarna
13:30 CET | Stockholm, Sweden
Join CEO Bent Frandsen for a live update at Aktiespararna’s Stora Aktiedagen in Stockholm. You can stream the event via Aktiespararnas YouTube channel or aktiespararna.se/tv/live. Read more and register on Aktiespararna's website.
7 March 2024 | Swiss Nordic Bio 2024
Zurich, Switzerland
ExpreS2ion CFO Keith Alexander will present ExpreS2ion to investors and potential investors. Registration is possible via the Swiss Nordic Bio website.
18-20 March 2024 | BIO-EUROPE Spring
Barcelona, Spain
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expres2ionbio.com. More information is available at BIO-Europe’s website.
19-21 March 2024 | Bioprocessing Summit Europe
Barcelona, Spain
ExpreS2ion Senior Vice President of R&D and Technology Dr. Max Søgaard is invited to present in the Cell Line Development track. His presentation will be on 21 March on the topic, "Industrial Use of Drosophila S2 Cells for Production of Highly Immunogenic Antigens," and will be presented with a parallel virtual feed. For more information and to attend the event, please visit the Bioprocessing Summit Europe website. To set up a meeting with Dr. Søgaard, please send a meeting request to info@expres2ionbio.com.
20 March 2024 | Økonomisk Ugebrev
Copenhagen, Denmark
ExpreS2ion CFO Keith Alexander will present the ExpreS2ion investment case to investors and potential investors. More information and registration is possible via the event website.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.